Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables. The company also provides contract research organization (CRO) that offers personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. The company markets and sells its STREAMWAY Fluid Waste Management system and procedure disposables to medical facilities through various direct sales force and independent distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was founded in 2002 and is based in Eagan, Minnesota.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone651-389-4800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.41 million
Profitability
Miscellaneous
Employees24
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Precision Therapeutics (NASDAQ:POAI) Frequently Asked Questions
What is Precision Therapeutics' stock symbol?
Precision Therapeutics trades on the NASDAQ under the ticker symbol "POAI."
How were Precision Therapeutics' earnings last quarter?
Precision Therapeutics Inc (NASDAQ:POAI) posted its quarterly earnings results on Monday, August, 19th. The medical instruments supplier reported $0.02 earnings per share for the quarter. The medical instruments supplier had revenue of $0.29 million for the quarter. Precision Therapeutics had a negative return on equity of 122.54% and a negative net margin of 657.73%. View Precision Therapeutics' Earnings History.
When is Precision Therapeutics' next earnings date?
Has Precision Therapeutics been receiving favorable news coverage?
News headlines about POAI stock have trended somewhat positive on Wednesday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Precision Therapeutics earned a news sentiment score of 0.6 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Precision Therapeutics.
Who are some of Precision Therapeutics' key competitors?
What other stocks do shareholders of Precision Therapeutics own?
Who are Precision Therapeutics' key executives?
Precision Therapeutics' management team includes the folowing people:
- Dr. Carl I. Schwartz, CEO & Director (Age 78)
- Mr. Robert L. Myers, CFO & Sec. (Age 64)
- Mr. David Orrin Johnson, Sr. VP of Operations - Skyline Medical Bus. Unit (Age 66)
- Mr. Kevin Hungerford, VP of Sales & Marketing
How do I buy shares of Precision Therapeutics?
Shares of POAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Precision Therapeutics' stock price today?
One share of POAI stock can currently be purchased for approximately $0.42.
How big of a company is Precision Therapeutics?
What is Precision Therapeutics' official website?
How can I contact Precision Therapeutics?
Precision Therapeutics' mailing address is 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121. The medical instruments supplier can be reached via phone at 651-389-4800 or via email at [email protected]
MarketBeat Community Rating for Precision Therapeutics (NASDAQ POAI)
MarketBeat's community ratings are surveys of what our community members think about Precision Therapeutics and other stocks. Vote "Outperform" if you believe POAI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe POAI will underperform the S&P 500 over the long term. You may vote once every thirty days.
